gsk clinical trials, page-18

Indeed, it appears that launch pad at issue price is established.
Baker will push this up from here, in my opinion, as soon as CR developments become concrete, should not be long and within this current calendar month.


Possible license agreements to be expected realistically in 2014, as I read developments between Coty, P&G and now GSK.

That might arrive too late for the directors performance shares to be issued and make therefore our in house program a priority in order to achieve all milestones attached as conditions for the issuance of those shares.

Our broker, from here onwards, should be now able to move price accordingly to guarantee a much greater participation of shareholders in the CR.